chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Presented to the hospital on 5/17/23 with flank pain, cough, and yellow sputum. Tested positive for COVID. He was treated and discharged on 6/2/23.
Hives on face, trunk, and arms 4 hours after vaccine administration. Worst hives on left arm where shot was administered.
Rash started 24 hours after receiving MENVEO vaccine on left upper arm. Redness and warmth started there, now resolved, but redness and swelling in wrists and hands bilaterally some redness on thighs. Not itchy, not painful.
High Fever (over 104) lasted 10 days, diagnosed with double ear infection, next day rash came, Rash covered patients entire body. Next day rash still present, along with fever, even with antibiotics (azithromycin), took pt to hospital. Diagnosed with pneumonia, had 1 lb weight loss, diarrhea. Admitted to hospital, fever broke, rash went away, ear infection still present, had seizure. Continued to have small seizures throughout the day. Next day pt released from hospital home 24 hours when fever came back, along with another seizure. Pt has not been taken back to hospital yet, symptoms still present. This is day 14.
Shoulder injury related to vaccine administration  Rotator cuff type pain starting 2 hours after vaccine and persisting 2 weeks later.  Pain in shoulder daily despite ibuprofen every 6 hours.  Range of motion limited severely.
ADMINISTERED PUNCTURED VACCINE LEFT AT ROOM TEMPERATURE FOR 5.5 HOURS; PUNCTURED VACCINE STORED AT ROOM TEMPERATURE FOR 5.5 HOURS; This spontaneous report received from a pharmacist concerned a 38 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine (suspension for injection, intramuscular, batch number: 041A21A expiry: 19-SEP-2021) dose was not reported, administered on 10-SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-SEP-2021, the patient experienced administered punctured vaccine left at room temperature for 5.5 hours. On 10-SEP-2021, the patient experienced punctured vaccine stored at room temperature for 5.5 hours. The action taken with covid-19 vaccine was not applicable. The outcome of the administered punctured vaccine left at room temperature for 5.5 hours and punctured vaccine stored at room temperature for 5.5 hours was not reported. This report was non-serious.
Information has been received from a registered nurse concerning a female patient , who on 19-JAN-2011 was vaccinated with a dose of GARDASIL (Lot # not reported). The nurse reported that the mother of the patient reported that the patient was experiencing vaginal bleeding and a temperature of 102 degrees Fahrenheit. The nurse reported that the mother stated that the interval between patient's menses were normally very regular, and that this bout of vaginal bleeding was approximately 2 weeks earlier than anticipated during the patient's cycle. It was reported that the patient did not receive treatment for the adverse event. The patient sought medical attention via telephone call to immunizing facility. At the time of the report, the patient's outcome was unknown. No further information is available.
Missed dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication was reported No concomitant medication was reported   Reporter did not allow further contact
Arm was itchy; A little arm soreness; A rash; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Arm was itchy), PAIN IN EXTREMITY (A little arm soreness) and RASH (A rash) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history ).    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRURITUS (Arm was itchy), PAIN IN EXTREMITY (A little arm soreness) and RASH (A rash). At the time of the report, PRURITUS (Arm was itchy), PAIN IN EXTREMITY (A little arm soreness) and RASH (A rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided  by the reporter.  Treatment information was not provided.
ELEVATED TEMP 100.3, SHORTNESS OF BREATH, LOW OXYGEN SATURATION LEVEL, LETHARGY
More than 24 hours of Shivering, Excruciating  headache, muscle, articulations pain and mild  fever.
CHILD PRESENTED AT EVENT REQUESTING SECOND DOSE IN PRIMARY SERIES. RECEIVED GIFT CARD INCENTIVE FOR COMPLETING SERIES. DISCOVERED DURING DATA ENTRY THAT CHILD HAD ALREADY RECEIVED DOSE #2 AT ON 12/14/2021.  THEREFORE, THIS WAS AN UNAUTHORIZED EXTRA DOSE 1 WEEK FOLLOWING THE LAST DOSE.
Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures; Literature Report.   Information has been received from the authors of a published literature article, title as stated above regarding to a child patient of an unknown gender. No information was provided regarding the patient's medical history, concurrent conditions and concomitant therapies.  On an unknown date, the patient was vaccinated with at least the first dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) to prevent measles (dose, vaccination scheme, route of administration, anatomical injection site, lot number and expiration date were not reported).  On an unknown date, the patient experienced localization-related (focal) (partial) epilepsy and epileptic syndromes with simple partial seizures (partial seizures). At the time of the report, the outcome of the event was not reported.  The authors considered that the event partial seizures was considered to be related to suspect vaccine as this event was considered a rare consequence of routine childhood measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) vaccination.  Upon internal review, the event partial seizures was determined to be medically significant.   A copy of the published article is attached as further documentation of the patient's experience.  This is one of several reports received from the same reporter (MARRS# 2010USA001144).; Sender's Comments:  US-009507513-2010USA001144:
Patient had Varivax on 2/22/08 - had a seizure on 2/28/08.
About 5 minutes after receiving the shot, my upper lip started tingling. Then both upper and lower lips were tingling. I could drink ok, so no problem swallowing. They took my blood pressure at the time and it was 104/55. I have low blood pressure but that was lower than normal. I stayed for 30 minutes and the tingling would come and go. They did offer to call an ambulance but I declined. I got up this morning and have 2 welts on my forehead and the left side of my lips are still tingling, and occasionally the right side. I will call my doctor tomorrow morning.
Information has been received from a nurse referring to an unspecified number of patients of unknown age and gender. No concurrent or historical conditions were reported. On 09-SEP-2015, the patients were inadvertently vaccinated with improperly stored doses of GARDASIL 9 (lot# L011846, expiration date 16-JUN-2017, strength, dose and route unknown). No adverse events had been reported. This is one of several reports received from the same reporter. Additional information has been requested.
Immediately following the administration of the vaccine on Thursday, I tasted a metallic taste.  Within 5 mins I began to having a racing heart and flushed skin.  On my drive home approximately 15-20 minutes following the administration of the vaccine, I began feeling very flushed, continued racing heart, and had a lot of difficulty swallowing.  I tried to push water even though it was difficult to swallow.  Upon getting home I continued to feel these symptoms along with fatigue.  I laid down to rest after feeling extremely fatigued.  30 minutes later I woke up (this is approximately 1 hour - 1.5 hours after the vaccine administration) with a rash all over my chest, my neck and face.  Additionally, the left side of my neck was extremely swollen.  The lymph node on the left side was sticking out about the size of a golf ball.  I continued to have all these symptoms along with then extreme nausea, hot/cold flashes, and flu-like symptoms.   I took three Advil at this time.  These symptoms continued onto the morning (Friday).  In the morning, I still had the rash and swollen neck, so being worried, I took Benedryl and contacted my doctor and sent him pictures of my allergic reaction.  By Sunday, the swelling in my neck and other symptoms subsided.  The doctor returned my message on Monday and instructed me to report this via this form and advised me not to get the second shot, as it looks like  I had a severe allergic reaction to the first vaccine.  He advised me at that time that if I was still having symptoms I should go to the ER.  I no longer was having those symptoms, so I did not go to the ER immediately.
ER 12/8/21 weakness, stuttering, Back pain, neck pain 12/10/21 chest pain, weakness, need for nitroglycerin that was atypical
Sore arm, sore throat, chill. Swollen glands, running nose then get congested. A little bit of fever.
development of facial swelling; rash; This spontaneous report was received from a health professional (Nurse practitioner) refers to a 10-year-old female patient. The patient's concurrent conditions and medical history were not provided. Concomitant medications included diphtheria toxoid (+) pertussis acellular 5-component vaccine (+) tetanus toxoid (ADACEL) and meningococcal ACYW conj vaccine (dip toxoid) (MENACTRA).   On an unknown date in 2016 (reported as 3 years ago), the patient was vaccinated with first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) via intramuscular route for prophylaxis (Lot # and expiry date unspecified).             On an unknown date in 2016 (reported as 3 years ago), after the first dose of vaccine the patient experienced facial swelling and later a rash (not specified).  As per nurse practitioner, this was first time to hear of this reaction and there was no treatment given to patient at the time of first dose hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9).    The patient was in the office for unspecified reason recently and nurse practitioner stated patient' s mother refused second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) in immunization series as patient experienced a reaction after first dose. No cancer adverse event. The patient did not die. No significant disability and hospitalization. No Life-threatening events. No overdose. No PQC involved. No further information provided.     Therapy with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) was discontinued. The outcome of swelling face and rash was resolved.
Diarrhea; Blood in stools; This spontaneous case was reported by a consumer and describes the occurrence of HAEMATOCHEZIA (Blood in stools) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-May-2021, the patient experienced HAEMATOCHEZIA (Blood in stools) (seriousness criterion medically significant). On an unknown date, the patient experienced DIARRHOEA (Diarrhea). At the time of the report, HAEMATOCHEZIA (Blood in stools) and DIARRHOEA (Diarrhea) had not resolved.            No relevant concomitant medications were reported. Treatment of the event diarrhea included, antibiotics. After a week and a half of second dose reporter started with severe diarrhea. Diarrhea stopped and restarted on 21-May-2021, with blood in stools. Action taken with mRNA-1273 in response to the events was not applicable  Very limited information regarding this event/s has been provided at this time.  Further information has been requested.; Sender's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.
arm is sore; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 28Sep2021 (Lot number: 301558A, Expiration Date: 31Dec2021) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 2, single, No events reported), for Covid-19 immunization, reaction(s): "No adverse events"; Bnt162b2 (Dose 1, single, No events reported), for Covid-19 immunization, reaction(s): "No adverse events".  The following information was reported: PAIN IN EXTREMITY (non-serious) with onset Sep2021, outcome "unknown", described as "arm is sore".  No follow-up attempts are possible. No further information is expected.
No additional AE; Caller reported that PROQUAD that underwent a temperature excursion was administered.; This spontaneous report has been received from a nurse concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history, concomitant therapies and drug/allergy history were not reported.  On 31-AUG-2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) (lot # W010061, has been verified to be a valid lot number for measles, mumps, rubella and varicella [oka-merck] virus vaccine live [rHA] [PROQUAD], expiration date reported and upon internal validation established as 20-SEP-2023) (dose, anatomical location and route of administration were not reported). The vaccine was administered for prophylaxis after a temperature excursion (temperature of -14 Celsius degrees [°C] up to -10°C [-14.18C] for 0 hours 15 minutes and 0 seconds) (Product storage error). The vaccine did not have previous temperature excursions.  No adverse event was reported.  This is one of three cases reported by the same reporter.
Mom says pt woke up with all over body itchy red rash this morning.  She further states he had a fever 2 days ago.
Information has been received from a registered nurse concerning a patient (age and gender not reported) who on 24-OCT-2006 was vaccinated with Pneumovax 23 (lot # 651356/0089F). Concomitant medication was not reported. On 24-OCT-2006 (later the same day), the patient experienced a cellulitis-like reactions in which the arm where the vaccine was administered swelled and became red and swollen from the elbow to the shoulder. The current status of the patient was reported as unknown. The nurse stated that he was unaware of the patient missing any work because of the reaction. Follow-up information has been received. The records of testing prior to release of the lot in question have been rechecked and found to be satisfactory. The lot met the requirements of Center for Biologics Evaluation and Research and was released. Additional information has been requested.
Immunization given 4/18/06. Approximately 24 hours later redness and swelling of arm from elbow to shoulder. Pruritus.
The patient had a red, raised rash starting at his trunk and spreading out toward his limbs for two days. The rash did not bother the patient and there was no treatment.
Day after vaccine experienced weakness, chills fatigue. Day four felt better went snowboarding and balance was off and fell several times.  Body aches and pain continued.  12/29/2020 at 8 pm had fever of 100.  12/30 fever 103f chills, slept almost all day loss of appetite.   12/31 no fever in the morning but acting different than normal.  In after non could not tell my husband child?s name went to the ED where I was admitted for altered mental status.   Discharge today with altered mental status, unspecified.  Wife still has headache but normal level of consciousness.
This is an instance of breakthrough COVID-19 disease after which death occurred.   The individiual was vaccinated with the Pfizer product on 03/12/2021 and 04/02/2021.   They became symptomatic for COVID-19 disease on approx 08/13/2021 and presented to emergency department on 08/17/2021 for shortness of breath. They were found to be hypoxic and  were admitted to hospital on 08/17/2021. The individual tested positive for COVID-19 via PCR test on 08/17/2021 and a second PCR test on 08/19/2021 was also positive. They were diagnosed with COVID-19 pneumonia. Their health deteriorated and they died on 08/21/2021.  This individual had several complex, underlying medical conditions.
Papules used BENADRYL and cortisone. Pt experienced severe case of hives over torso and legs ankle and feet. Hives lasted 4 days. Pt was given BENADRYL.
No adverse event; patient received expired first dose; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient received expired first dose) and NO ADVERSE EVENT (No adverse event) in a 19-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 071B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 14-Mar-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 14-Mar-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (patient received expired first dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient received expired first dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (patient received expired first dose).    No concomitant medication was reported.  It was unknown when the vial was initially stored in refrigerator. It was unknown the vial undergo temperature excursions.  Expiration date was reported as 12-MAR-2023. No treatment information was reported.
Extreme fatigue like I had been up for 3 days and I had chills. I went to the couch around 10am and woke up at 4pm and it went downhill after that. I was still tired and had chills. I had body aches and would walk slowly like the tin man on The Wizard of Oz. Moving was painful. I had like a 12" stride. I had congestion, runny nose, and a headache that responded to Tylenol.
PT HAD SYNCOPE AND COLLAPSE AT TIME OF VACCINE ADMINISTRATION. SHE SLUMPED FORWARD AND HIT HEAD AGAINST SURFACE OF WORK TABLE AND SUFFERED A RIGHT EYEBROW  LACERATION AND CONCUSSION
Patient was fine  after vaccine administration, but while sitting down patient passed out while sitting next to her mother.  Patient was laid on the floor and regained consciousness while on the floor.  Eventually with other help, got patient into wheel chair.  Mom didn't want EMS called and just let patient sit for awhile until our store director in charge left with patient in wheel chair and Mom to make sure patient was alright.
pt to ED with c/o SOB, cough; positive for COVID; pt's condition declined during hospital stay; O2 requirement increased resulting in intubation; pt continued to decline and he died in the hospital
I was traveling, consulted with my doctor before hand because I am diabetic and about 65 and he gave me the green light. I know the COVID-19 cases is very low where I was traveling to, I never had any symptoms during the week I was there. I then flew to first layover, and visited my son and ate at a restaurant. Then flew to the nest lay over the next day, and developed symptoms about two days later, 07/02. First couple of days were the worst. It wasn't terrible, temperature of 100.2, very congested, sore throat, and some additional symptoms later on of headache, achiness. I never get headaches so that one was very unusual for me. I contacted my Doctor via email and he prescribed Paxlovid for me on July 5th, which was already 3 days in of symptoms. I spread it to my wife, her case was definitely more severe, and I think my dog contracted it as well, and a few friends I had contact. My symptoms went away after about 5 days and then came back about two days with the sore throat and bad congestion. Im still struggling with some of the symptoms.
DEVELOPED URTICARIA- HEADACHES- SWOLLEN LYMPH NODES UPPER LEFT SIDE OF CHEST AND RIGHT SIDE GROIN AREA.
Woke up with a rash and itchy chest; Itchy chest; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the right arm on 30Mar2021 at 11:00 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included sertraline (MANUFACTURER UNKNOWN), guaifenesin; pseudoephedrine hydrochloride (SUDAFED), estradiol (MANUFACTURER UNKNOWN) and cetirizine hydrochloride (ZYRTEC); all for unspecified indications from on an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 02Apr2021 at 08:00, the patient woke up with a rash and itchy chest. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the rash and itchy. The clinical outcomes of the events rash and itchy were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Started with intense abdominal pain and need to evacuate/nearly fainted                                                                                                                               Started to run a fever accompanied bu aching in joints, muscles, head.   The fever  has continued for two days (low grade 100.8 plus or minus No appetite for two days so far